by Michael Morgenstern, MD | Sep 18, 2018 | Blog, Health care, medical cannabinoids
On June 25th, 2018, the U.S. Food & Drug Administration (FDA) approved Epidiolex (cannabidiol, CBD) for treatment of seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome, two forms of epilepsy. Epidiolex is the first plant-based drug derived from...
Recent Comments